Safety and Efficacy Study of MBX-102 in Treatment of Hyperuricemia in Patients With Gout

This study has been completed.
Information provided by (Responsible Party):
CymaBay Therapeutics, Inc. Identifier:
First received: April 14, 2011
Last updated: August 24, 2012
Last verified: August 2012

April 14, 2011
August 24, 2012
May 2011
November 2011   (final data collection date for primary outcome measure)
Serum uric acid [ Time Frame: Baseline and end of treatment phase (4 wks) ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01336686 on Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
Safety and Efficacy Study of MBX-102 in Treatment of Hyperuricemia in Patients With Gout
A Phase 2 Randomized Double-Blind Placebo-Controlled Study to Evaluate the Safety and Efficacy of MBX-102 in the Treatment of Hyperuricemia in Patients With Gout

The purpose of the study is to evaluate the safety and effectiveness of MBX-102 compared to placebo when given orally once daily for 4 weeks for the treatment of hyperuricemia in patients with gout.

Not Provided
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
  • Hyperuricemia
  • Gout
  • Drug: Arhalofenate
    Arhalofenate 400 mg once daily for 4 weeks
    Other Name: MBX-102
  • Drug: Arhalofenate
    Arhalofenate 600 mg once daily for 4 weeks
    Other Name: MBX-102
  • Drug: Placebo comparator
    Matching placebo once daily for 4 weeks
  • Experimental: Arhalofenate 400 mg
    Intervention: Drug: Arhalofenate
  • Experimental: Arhalofenate 600 mg
    Intervention: Drug: Arhalofenate
  • Placebo Comparator: Placebo
    Intervention: Drug: Placebo comparator
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
November 2011
November 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Read and sign the informed consent after the elements of consent have been fully explained and all questions have been addressed, prior to any study procedures.
  • Known gout patient (per criteria of the American Rheumatism Association for the classification of the acute arthritis of primary gout in Appendix 3)

    • the sUA must be ≥ 8.0 mg/dL and ≤12 mg/dL
    • if on ULT, the patients must agree to temporarily discontinue their existing ULT and the sUA must be ≥ 8.0 mg/dL and ≤12 mg/dL after wash-out at Week -1
  • Male or female, 18-75 years of age at Screening Visit
  • All female patients must be surgically sterile or post-menopausal (at least 45 years of age with no history of menses for at least 2 years; or any age with no history of menses for at least 6 months and serum FSH ≥ 40 mIU/mL) or have a partner who has undergone vasectomy or must agree to use two medically accepted methods of contraception including a barrier method (see the list in Appendix 4) for the entire duration of the study unless reporting complete sexual abstinence.
  • Female patients must not be pregnant or lactating
  • Male patients with a female partner of child-bearing potential must agree to use condom or the partner must use a medically acceptable method of contraception for the entire duration of the study.
  • Patients must have an estimated CrCl ≥ 60 mL/min as calculated by the Cockcroft-Gault method
  • Serum creatinine value must be ≤ 1.1 mg/dL in females and ≤ 1.3 mg/dL in males
  • Patients must have liver function tests ≤ 1.5X ULN for AST, ALT and T-bilirubin, ≤ 2X ULN for ALP, ≤ 3X ULN for GGT; and ≤ 3X ULN for CK
  • All other clinical laboratory parameters must be within normal limits or considered not clinically significant for participation in this study
  • Electrocardiogram (ECG) must be normal, or if abnormal, considered not clinically significant for participation in this study
  • Patients must have a systolic blood pressure ≤ 160 mm Hg and a diastolic blood pressure ≤ 90 mm Hg; known hypertensive patients controlled with medication other than thiazide diuretics (BP reading as above) may be included

Exclusion Criteria:

  • Known or suspected secondary hyperuricemia (e.g. due to myeloproliferative disorder, or organ transplant).
  • Known patient with xanthinuria
  • History of documented or suspected kidney stones
  • Over producers of uric acid as evidenced by 24-hour urinary uric acid > 800 mg (on normal unrestricted diet)
  • Known infection with the human immunodeficiency virus (HIV) or history of viral hepatitis type B or C
  • History of illicit drug or alcohol abuse within last 1 year
  • History of significant pulmonary disease, upper GI bleeding, documented peptic ulcer disease (unless known H. pylori infection treated successfully without recurrence), or nephrotic syndrome within last 3 years
  • All patients must not have had a stroke, TIA, acute myocardial infarction, congestive heart failure (NYHA Class II-IV), angina pectoris, coronary intervention procedure (including but not limited to angioplasty, stent placement, coronary revascularization), lower extremity bypass procedure, systemic or intracoronary fibrinolytic therapy within last 5 years
  • Malignancy within the last 5 years (except resected basal cell carcinoma)
  • Body mass index (BMI) > 42 kg/m2
  • Current or expected requirement for anticoagulant therapy (except for ≤ 325 mg/day aspirin and/or Plavix® 75 mg/day)
  • Rheumatoid arthritis or other autoimmune disease requiring ongoing treatment
  • Current or expected treatment with potent CYP3A4 inhibitors (See in Appendix 6), ranolazine, digoxin, cyclosporine, cyclophosphamide and other cytotoxic agents, sulphonylurea, thiazolidinedione, diuretic, atypical antipsychotic agents, and phenytoin
  • Chronic treatment with non-steroidal anti-inflammatory drugs (NSAIDs use to treat acute flares are permitted)
  • Current or expected treatment with systemic corticosteroids (except topical, ophthalmic, intra-articular, or inhaled at a dose < 1600 μg/day) other than to treat acute flares
  • Known hypersensitivity to colchicine
  • Treatment with any other investigational therapy within the 30 days prior to the Screening Visit, or patients who received at least one dose of blinded study drug while enrolled in any previous MBX-102 trial
  • Any other condition that compromises the ability of the patient to provide informed consent or to comply with the objectives and procedures of this protocol, as judged by the investigator and/or medical monitor
18 Years to 75 Years
Contact information is only displayed when the study is recruiting subjects
United States
CymaBay Therapeutics, Inc.
CymaBay Therapeutics, Inc.
Not Provided
Not Provided
CymaBay Therapeutics, Inc.
August 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP